Acasti's krill oil-derived drug fails late-stage study, shares tumble

Acasti Pharma Inc said on Monday its krill oil-derived drug candidate, CaPre, failed to show a statistically significant reduction in a type of fat found in blood compared to placebo in a late-stage study, sending its shares down 54%.

from Reuters: Health News https://ift.tt/2tRni3M